全文获取类型
收费全文 | 444篇 |
免费 | 19篇 |
国内免费 | 5篇 |
专业分类
儿科学 | 18篇 |
妇产科学 | 4篇 |
基础医学 | 30篇 |
口腔科学 | 15篇 |
临床医学 | 36篇 |
内科学 | 84篇 |
皮肤病学 | 1篇 |
神经病学 | 22篇 |
特种医学 | 91篇 |
外科学 | 38篇 |
综合类 | 19篇 |
预防医学 | 26篇 |
眼科学 | 17篇 |
药学 | 24篇 |
肿瘤学 | 43篇 |
出版年
2022年 | 3篇 |
2021年 | 7篇 |
2020年 | 5篇 |
2019年 | 3篇 |
2018年 | 9篇 |
2017年 | 5篇 |
2016年 | 7篇 |
2015年 | 16篇 |
2014年 | 8篇 |
2013年 | 23篇 |
2012年 | 21篇 |
2011年 | 12篇 |
2010年 | 19篇 |
2009年 | 12篇 |
2008年 | 16篇 |
2007年 | 16篇 |
2006年 | 13篇 |
2005年 | 9篇 |
2004年 | 11篇 |
2003年 | 5篇 |
2002年 | 5篇 |
2001年 | 9篇 |
2000年 | 6篇 |
1999年 | 7篇 |
1998年 | 19篇 |
1997年 | 21篇 |
1996年 | 17篇 |
1995年 | 13篇 |
1994年 | 15篇 |
1993年 | 9篇 |
1992年 | 4篇 |
1991年 | 5篇 |
1990年 | 8篇 |
1989年 | 10篇 |
1988年 | 9篇 |
1987年 | 6篇 |
1986年 | 10篇 |
1985年 | 11篇 |
1984年 | 8篇 |
1982年 | 5篇 |
1981年 | 6篇 |
1980年 | 9篇 |
1978年 | 5篇 |
1977年 | 6篇 |
1976年 | 3篇 |
1975年 | 4篇 |
1973年 | 2篇 |
1958年 | 2篇 |
1954年 | 2篇 |
1953年 | 2篇 |
排序方式: 共有468条查询结果,搜索用时 15 毫秒
11.
12.
13.
High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy 总被引:2,自引:1,他引:2
Brown RA; Herzig RH; Wolff SN; Frei-Lahr D; Pineiro L; Bolwell BJ; Lowder JN; Harden EA; Hande KR; Herzig GP 《Blood》1990,76(3):473-479
Seventy-five patients with resistant acute leukemia or lymphoma received high-dose cyclophosphamide and etoposide to explore the activity of this combination in resistant hematologic malignancies, and to determine the maximum doses of these drugs that can be combined without bone marrow transplantation. Etoposide was administered over 29 to 69 hours by continuous infusion corresponding to total doses of 1.8 g/m2 to 4.8 g/m2. Cyclophosphamide, 50 mg/kg/d, was administered on 3 or 4 consecutive days total 150 to 200 mg/kg ideal body weight). At all dose levels myelosuppression was severe but reversible. Mucosal toxicity was dose-limiting with the maximum tolerated dose level combining etoposide 4.2 g/m2 with cyclophosphamide 200 mg/kg. Continuous etoposide infusion produced stable plasma levels that were lower than would be achieved after administration by short intravenous infusion, and this could explain our ability to escalate etoposide above the previously reported maximum tolerated dose. There were 28 complete (35%) and 12 partial (16%) responses. Median duration of complete response (CR) was 3.5 months (range 1.1 to 20+). Seventeen of 40 patients (42%) with acute myelogenous leukemia (AML) achieved CR, including 6 of 20 (30%) with high-dose cytosine arabinoside resistance. We conclude that bone marrow transplantation is not required after maximum tolerated doses of etoposide and cyclophosphamide. This regimen is active in resistant hematologic neoplasms, and the occurrence of CR in patients with high-dose cytosine arabinoside-resistant AML indicates a lack of complete cross-resistance between these regimens. 相似文献
14.
15.
16.
Maples Natalie J. Velligan Dawn I. Jones Eric C. Espinosa Erin M. Morgan Robert O. Valerio-Shewmaker Melissa A. 《Community mental health journal》2022,58(3):578-588
Community Mental Health Journal - There is increased interest over the last decade in the use of Shared Decision Making with individuals with serious mental illness to improve engagement in... 相似文献
17.
Human red cells (RBCs) were collected in CPDA-1 and then freeze-dried in lyoprotective solution. The lyophilized RBCs were then stored at -20 degrees C for 7 days. At the end of the storage period, the lyophilized RBCs were rehydrated and washed in dextrose saline. The washed, reconstituted, lyophilized RBCs were resuspended in final wash solutions of ADSOL, CPDA-1, or a special additive solution containing glucose, citrate, phosphate, adenine, and mannitol, and then they were stored at 4 degrees C for an additional 7 days. The main purpose of this study was to determine whether human RBCs can be lyophilized in such a manner that normal metabolic, rheologic, and cellular properties are maintained during rehydration and subsequent storage in standard blood bank preservative solutions. Our results show that reconstituted, lyophilized RBCs maintained levels of ATP, 2,3 DPG, lactate, and cellular properties that are equal to or better than those in control nonlyophilized RBCs stored for a comparable period in CPDA-1. Reconstituted, lyophilized RBCs stored at 4 degrees C after rehydration also show better maintenance of ATP, 2,3 DPG, and lactate than do control RBCs stored in the same preservative solutions for comparable periods. 相似文献
18.
19.
SUSAN F. VERVOORDELDONK PAULINE A. MERLE HENK BEHRENDT ERIC J. STEENBERGEN HENK VAN DEN BERG ELISABETH R. VAN WERING ALBERT E. G. KR. VON DEM BORNE C. ELLEN VAN DER SCHOOT ELEONORE F. VAN LEEUWEN & INEKE C. M. SLAPER-CORTENBACH 《British journal of haematology》1997,96(2):395-402
Purging of autologous bone marrow (BM) grafts of children in second remission after a relapse of precursor B acute lymphoblastic leukaemia (ALL) in the BM has been carried out in our laboratory since 1987, initially by complement mediated cell lysis. This protocol was extended by performing an immunorosette depletion before lysis with complement. The aim of the present study was to assess by polymerase chain reaction the presence of residual leukaemic cells in the BM grafts before and after purging. The results were then correlated to clinical outcome. In 24/28 patients a PCR product was obtained by amplification of IgH and/or TcR junctional regions. BM before purging was available for analysis in 13 patients. We found that leukaemic cells could be detected in 8/13 (62%) of these grafts before purging . All these eight patients experienced a relapse, regardless of whether the purging procedure had been successful (defined as achievement of PCR-negativity) or not. In contrast, none of the five patients with PCR-negative grafts before purging relapsed ( P = 0.0008). One patient died due to transplant-related toxicity. Of the remaining 23 patients, nine patients received a PCR-positive BM graft after purging. All these nine patients experienced a relapse as compared to 6/14 whose BM was PCR-negative after purging ( P = 0.0072). Two of eight PCR-positive BM grafts could be purged to PCR-negativity. Thus, improvements both in treatment of leukaemia and in purging efficacy are still needed. 相似文献
20.